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Whether chemosensitivity, as determined by positron emission tomography using ﬂuorine-18-deoxyglucose
(FDG-PET), is a requirement for successful allogeneic hematopoietic stem cell transplantation (allo-SCT) has
yet to be established. We analyzed 88 patients with B cell non-Hodgkin lymphoma (B-NHL) for event-free
(EFS) and overall survival (OS) according to computed tomography (CT) and FDG-PET criteria before uni-
form nonmyeloablative (NMA) allo-SCT. Patients who were chemosensitive, according to CT criteria, expe-
rienced signiﬁcantly greater EFS (P < .001) and OS (P < .03) compared with those who were chemorefractory
at the time of allo-SCT. Of 58 patients within this cohort who were chemosensitive by CT criteria, there was no
difference in EFS (P ¼ .85) or OS (P ¼ .96) between FDG-PETepositive (Deauville 4 to 5, n ¼ 24) and FDG-PET
enegative (Deauville 1 to 3, n ¼ 34) patients. There was no difference in survival according to age < or 
60 years, prior autologous-stem cell transplantation, allograft characteristics, or histology. FDG-PET adds no
prognostic value in chemosensitive B-NHL before NMA-allo-SCT.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Although high-dose chemotherapy followed by autolo-
gous stem cell transplantation (HDT-ASCT) is a standard
treatment approach for relapsed and refractory diffuse large
B cell lymphoma (DLBCL) [1], the most common B cell non-
Hodgkin lymphoma (B-NHL), recent data suggest many
failures of this treatment modality in the post-rituximab era
[2]. Additionally, HDT-ASCT is considered unlikely curative
for patients with indolent histology B-NHL, such as follicular
and mantle cell (MCL) lymphoma. Allogeneic hematopoietic
stem cell transplantation (allo-SCT) is increasingly utilized
for relapsed and refractory B-NHL with the intent that a
graft-versus-lymphoma effect will provide disease control
and, ultimately, cure in patients at risk of succumbing to their
otherwise poor prognostic disease.dgments on page 883.
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14.02.009Functional imaging by ﬂuorine-18-deoxyglucose posi-
tron emission tomography (FDG-PET) is a more accurate
modality for assessing response to therapy, and viable tu-
mor, in patients with Hodgkin lymphoma (HL) and most
subtypes of indolent and aggressive NHL, compared with
computed tomography (CT) criteria [3]. Disease response to
salvage therapy by FDG-PET before HDT-ASCT has demon-
strated prognostic signiﬁcance in both HL [4,5] and NHL
[5,6]. Recently, interim response criteria have been estab-
lished according to the Deauville meeting [7]. Although
multiple studies have reproduced the signiﬁcant prognostic
impact of chemosensitivity before allo-SCT based upon CT
response criteria [8], there are no data pertaining to
the prognostic value of contemporary FDG-PET interim
response criteria [7] in B-NHL patients who are chemo-
sensitive before conventional nonmyeloablative (NMA)
allo-SCT.METHODS
Patients and Treatment
We retrospectively reviewed a database of 88 adult patients with
relapsed or primary refractory B-NHL who underwent uniformly condi-
tioned NMA allo-SCT at Memorial Sloan-Kettering Cancer Center (MSKCC)
for relapsed and refractory B-NHL from February 2006 to October 2012.
Table 1
Patient Characteristics
Characteristic Value
No. of patients 88
Age, median (range), yr 54 (33-70)
Histology
DLBCL 15 (17%)
FL 34 (39%)
MCL 11 (12.5%)
CLL/SLL 24 (27%)
Other 4 (4.5%)
WHO histologic subtypes
Indolent 73 (83%)
Aggressive 15 (17%)
HCT-CI, median (range) 1 (0-8)
Prior therapies, median (range) 2 (1-6)
Prior HDT-ASCT 15 (17%)
Disease status at allo-SCT per CT
CR 37 (42%)
PR 34 (39%)
SD 14 (16%)
PD 3 (3%)
Chemosensitive by CT (n ¼ 58)
FDG-PET (þ) 24 (41%)
DLBCL 4
FL 12
MCL 2
CLL/SLL 6
FDG-PET (-) 34 (59%)
DLBCL 8
FL 15
MCL 4
CLL/SLL 4
Other 3
Graft
Related 32 (35%)
Unrelated 56 (65%)
MUD 47
MMUD 9
Peri-NMA SCT rituximab
Yes 79 (90%)
No 9 (10%)
DLBCL indicates diffuse large B cell lymphoma; FL, follicular lymphoma;
MCL, mantle cell lymphoma; CLL, chronic lymphocytic leukemia; SLL, small
lymphocytic lymphoma; WHO, World Health Organization; HCT-CI, he-
matopoietic cell transplantation comorbidity index; Allo-SCT, allogeneic
stem cell transplant; CR, complete remission; PR, partial remission; SD,
stable disease; PD, progression of disease; MUD, matched unrelated donor;
MMUD, mismatched unrelated donor.
Data presented are n (%) unless otherwise indicated.
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Review and Privacy Board at MSKCC. Fifty-one of these patients were
treated on a prospective phase II clinical trial, MSKCC IRB #06-150
(NCT00425802) [9]. Patients with aggressive histology B-NHL by World
Health Organization criteria were required to demonstrate chemo-
sensitivity, either complete or partial remission, to salvage therapy as
determined by International Working Group Criteria [10] before allo-SCT.
Patients with indolent histology B-NHL, including chronic lymphocytic
leukemia/small lymphocytic lymphoma (CLL/SLL), had to have previously
failed at least 1 line of combination chemotherapy, though chemo-
sensitivity was not required. Patients with MCL were eligible in ﬁrst
remission if primary histology was either blastoid histology or p53
expressing on immunohistochemistry. Patients required a fully matched
or single HLA allele disparate related or unrelated donor at 10-loci (HLA-A,
HLA-B, HLA-C, HLA-DRb, or HLA-DQ).
Conditioning consisted of cyclophosphamide 50mg/kg for 1 dose on day
-6 followed by ﬂudarabine at 25 mg/m2 i.v. daily from day -6 to day -2. One
dose of total body irradiation at 200 cGy was delivered on day -1. Equine
antithymocyte globulin 30 mg/kg was given daily on day -3 and day -2 to
recipients of HLA-matched unrelated or HLA-single allele disparate allo-
grafts. Perieallo-SCT rituximab at 375 mg/m2 was given on day 8 or 7
and weekly for 4 doses, beginning day þ21 ( 2 days). Graft-versus-host
disease (GVHD) prophylaxis consisted of cyclosporine-A and mycopheno-
late mofetil (n ¼ 19) and later changed to tacrolimus, sirolimus, and
methotrexate day þ1, 3, and 6 at 5 mg/m2 (n ¼ 69).
Pre-NMA Allo-SCT CT and FDG-PET Scans
Chemosensitivity was assessed per standard CT criteria for B-NHL [10],
as well as additional criteria for CLL/SLL [11] before allo-SCT for all patients.
For patients who underwent FDG-PET before NMA-allo-SCTat the discretion
of the treating physician, Deauville criteria [7] were utilized wherein
Deauville 4 or 5 (FDG > background liver uptake or new FDG-avid lesions)
was considered a positive scan. A radiologist (S.F.) reviewed all images of
ambiguous results.
Statistical Analysis
Overall survival (OS) was the time from allo-SCT to death from any
cause, and surviving patients were censored at last follow-up. Event-free
survival (EFS) was the time from allo-HSCT to progression of disease or
death from any cause. The median and 3-year OS and EFS were estimated
using Kaplan-Meier methodology. OS and EFS in patients with different
characteristics were compared using the log-rank test.
RESULTS AND DISCUSSION
Eighty-eight patients with B-NHL underwent NMA allo-
SCT with uniform conditioning as above and 9 patients did
not receive peritransplantation rituximab per physician
decision. Table 1 outlines full patient characteristics. All
patients had been previously exposed to rituximab before
allo-SCT.
With a median follow-up of 37months (range, 4 to 75) for
survivors, the Kaplan-Meier estimates of OS and EFS at
3 years after NMA allo-SCT were 73% (95% conﬁdence in-
terval [CI], 63% to 83%) and 69% (95% CI, 58% to 79%),
respectively. The cumulative incidences of transplantation-
related mortality (TRM) and progression of disease (POD)
at 3 years were 21% (95% CI,11% to 30%) and 11% (95% CI, 4% to
18%), respectively. Analysis of pre-NMA allo-SCT character-
istics revealed no difference in EFS or OS among differing
B-NHL histologies, previous HDT-ASCT, hematopoietic cell
transplantationecomorbidity index of 0 to 1 versus  2, or
graft characteristics. Chemosensitive patients, according to
CT criteria, had signiﬁcantly improved EFS at 3 years
compared with patients who were chemorefractory (76%
[95% CI, 66% to 88%] versus 36% [95% CI, 18% to 71%]; P< .001)
(Figure 1A), which translated into OS beneﬁt at 3 years of 77%
(95% CI, 67% to 89%) versus 56% (95% CI, 36% to 87%); P ¼ .03.
Of the 71 chemosensitive, 3 events (4.2%) were relatable to
POD.There were 58 chemosensitive patients according to CT
criteria who additionally underwent restaging FDG-PET
scans before NMA allo-SCT. FDG-PET scans were per-
formed at a median of 30 days (range, 10 to 147 days)
before NMA-allo-SCT, with 93% of the FDG-PET scans per-
formed within 2 months of NMA-allo-SCT. There was no
intervening B-NHL therapy between preeallo-SCT FDG-PET
and allo-SCT. No differences in EFS or OS were demon-
strated between 34 patients achieving a negative FDG-PET
compared with the 24 with a positive FDG-PET, according
to Deauville interim restaging criteria (Figure 1B). The 4
events in the FDG-PETepositive group consisted equally of
TRM (n ¼ 2, both GVHD related) and POD (n ¼ 2), whereas
of the FDG-PETenegative patients, 5 events were relatable
to TRM (all GVHD) and 1 patient experienced POD. Of the
15 patients with DLBCL, 12 patients were chemosensitive
Figure 1. Event-free survival (A) according to chemosensitivity and (B) according to ﬂuorine-18-deoxyglucose positron emission tomography in chemosensitive
patients.
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these 12 patients were FDG-PET positive before allo-SCT,
with 1 patient subsequently experiencing POD after
allo-SCT.
This is the ﬁrst report demonstrating lack of prognostic
value of FDG-PET, according to contemporary consensus
response criteria [7], in chemosensitive B-NHL patients
undergoing conventional allo-SCT conditioned with a uni-
form NMA program. In studies to date, chemosensitivity, as
determined by traditional CT imaging, has reproducibly
affected OS in reduced-intensity (RIC)/NMA allo-SCT for
B-NHL [8]. This has been demonstrated with indolent
histology B-NHL [12,13], including prospectively in a
contemporary CLL/SLL study [14], as well as with aggressive
histology disease [15]. We have reproduced this ﬁnding
with signiﬁcant improvement in EFS and OS in chemo-
sensitive patients. However, herein, we demonstrate no
prognostic impact of normalizing FDG-PET scan below liver
uptake (Deauville score < 4) in those patients demon-
strating chemosensitivity by CT criteria [10,11] before con-
ventional NMA-conditioned allo-SCT. The group from
University College London has previously published similar
ﬁndings in chemosensitive patients proceeding to RIC allo-
SCT [16]. Their cohort differed from ours’ with respect to
use of in vivo T cell depletion with alemtuzumab and uti-
lization of older International Harmonization Project
criteria for FDG-PET restaging response [17]. Additionally,
their study included patients treated with risk-adapted
donor lymphocyte infusions after allo-SCT. A study con-
ducted by a group of Italian centers determined FDG-PET to
be prognostic in 80 chemosensitive patients with aggres-
sive histology NHL and HL proceeding to RIC allo-SCT from
related and unrelated donors [18]. This ﬁnding may be
attributable to the increased dependence of chemo-
sensitivity in aggressive histology lymphoma before RIC
allo-SCT, wherein graft-versus-lymphoma effects may
prove relatively belated in more rapidly kinetic disease.
Lastly, a small 14-patient study of lymphoma patients,
wherein 11 were FDG-PETepositive before allo-SCT, treated
with predominately myeloablative conditioning waspreviously reported without conclusive impact of FDG-PET
on prognosis [19].
Limitations of our study include the retrospective nature
and unplanned analysis in the patients undergoing this
uniform NMA allo-SCT treatment program toward the end-
points analyzed. Additionally, the relatively small numbers of
patients within the subhistologies of B-NHL potentially limits
the power of detecting differences in the primary endpoints
within these groups. Lastly, potential selection bias is intro-
duced given the physicians’ choice to obtain or not obtain
FDG-PET before NMA allo-SCT.
In conclusion, our study has found that FDG-PET scan
offers no prognostic beneﬁt for B-NHL patients before NMA
allo-SCT who have attained chemosensitivity by traditional
CT-based criteria. The majority of failure events (7 of 10) in
the chemosensitive patients who underwent FDG-PET scan
were TRM relatable to GVHD, underscoring the importance
of introducing more effective prophylaxis and treatment
strategies for this life-threatening complication. The limi-
tation of our study is the inclusion of heterogenous B-NHL
histologies, with the majority being indolent histology
disease. Although most of the predictive power of
preeHDT-ASCT FDG-PET is seen in patients with aggressive
histology lymphomas [4,5], FDG-PET has proven signiﬁ-
cantly prognostic for both 2-year progression-free and OS
on interim restaging during induction chemotherapy uti-
lizing the same criteria as our analysis [20]. Additionally,
positive FDG-PET for MCL, a disease considered of more
indolent histology relative to DLBCL or HL, has recently
demonstrated prognostic signiﬁcance for OS pre-HDT-ASCT
[21]. Findings from our study warrant prospective conﬁr-
mation. If prospectively validated, the lack of prognostic
signiﬁcance of positive FDG-PET in chemosensitive patients
before NMA allo-SCT would greatly reduce resources,
expense, and radiation exposure associated with FDG-PET
scans.
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